BPDCN patients treated with chemotherapy: a look back at real-world use

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study that collects data on BPDCN patients who received chemotherapy as their first-line treatment since May 2016. It aims to describe safety and effectiveness and to provide comparator data for the ELZONRIS STML-401-0521 registry. Participating centers will review medical records to capture demographics, treatment regimens, responses, and outcomes. The study does not assign treatments and does not intervene beyond data collection. Results will help contextualize how chemotherapy performs in real-world BPDCN care and how it compares to the ELZONRIS registry.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Alive, deceased, or unreachable participants (as permitted by local regulation), aged ≥18 years at the start of first-line treatment for BPDCN, and treated with chemotherapy regimens (at a minimum) as first-line treatment for BPDCN from May 2016
* Diagnosed with BPDCN, based on clinical, laboratory, and imaging (where performed per institutional practice) assessments, with a demonstration of a specific immunophenotype (either by immunohistochemistry or flow cytometry), particularly CD4, CD56, and CD123
* Participants (or their legally authorized representatives) who have signed the informed consent and privacy form, where required as per local regulation

Exclusion Criteria:

* Participant has received an investigational agent as first-line therapy for BPDCN
* Participant has received first-line therapy for BPDCN in an interventional clinical trial

Where it's running

• Aarhus University Hospital
  Aarhus, Denmark Recruiting
• Odense University Hospital
  Odense, Denmark Recruiting
• Centre Hospitalier Universitaire Besancon
  Besançon, France Recruiting
• Hôpital Avicenne
  Bobigny, France Recruiting
• Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut-Lévêque
  Bordeaux, France Recruiting
• Henri Mondor University Hospital
  Créteil, France Recruiting

+17 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Stemline Trials
• Email: clinicaltrials@menarinistemline.com
• Phone: 1-877-332-796

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tagraxofusp in BPDCN: Real-world Registry of Safety and Effectiveness

  This registry follows adults with BPDCN to see how tagraxofusp works in everyday clinical practice and how safe it is over time.

  Recruiting at 41 sites Stemline Therapeutics, Inc. · Innsbruck and 40 other locations · NCT07785154

• Tagraxofusp and venetoclax in newly diagnosed BPDCN

  This trial tests whether combining tagraxofusp with venetoclax can produce higher complete remissions in adults with newly diagnosed BPDCN.

  Recruiting at 8 sites Phase 2 French Innovative Leukemia Organisation · Amiens and 33 other locations · NCT07007052

• International registry for Blastic Plasmacytoid Dendritic Cell Neoplasm

  This study is creating a global database for people with Blastic Plasmacytoid Dendritic Cell Neoplasm to gather information on their experiences and treatments to help improve care for this rare cancer.

  Recruiting at 22 sites Immune Oncology Research Institute · Miami, Florida and 21 other locations · NCT05430971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.